These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32008334)

  • 1. Ramucirumab treatment in hepatocellular carcinoma.
    Longo F; Carrato A
    Chin Clin Oncol; 2020 Dec; 9(6):83. PubMed ID: 32008334
    [No Abstract]   [Full Text] [Related]  

  • 2. Ramucirumab and other new systemic therapies for hepatocellular carcinoma: still uncovered the problem of Child-Pugh B patients.
    Wilhelmi M
    Chin Clin Oncol; 2021 Jun; 10(3):33. PubMed ID: 33894701
    [No Abstract]   [Full Text] [Related]  

  • 3. Ramucirumab: A Review in Hepatocellular Carcinoma.
    Syed YY
    Drugs; 2020 Feb; 80(3):315-322. PubMed ID: 32034692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Ramucirumab
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
    Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yanagimoto H; Toyama H; Kodama Y; Fukumoto T
    Anticancer Res; 2021 Sep; 41(9):4555-4562. PubMed ID: 34475083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab and its use in the treatment of hepatocellular carcinoma.
    Turkes F; Chau I
    Future Oncol; 2019 Mar; 15(9):979-988. PubMed ID: 30644314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
    Roviello G; Sohbani N; Petrioli R; Rodriquenz MG
    Invest New Drugs; 2019 Dec; 37(6):1274-1288. PubMed ID: 30879152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
    Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M
    Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
    Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
    J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
    [No Abstract]   [Full Text] [Related]  

  • 13. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.
    Zhang Z; Zhou Y; Hu K; Li Z; Wang Z; Huang Y
    Dig Liver Dis; 2019 Oct; 51(10):1488-1490. PubMed ID: 31401020
    [No Abstract]   [Full Text] [Related]  

  • 14. Sintilimab plus IBI305 for hepatocellular carcinoma.
    Cheng L; Xiao H
    Lancet Oncol; 2021 Sep; 22(9):e387. PubMed ID: 34478671
    [No Abstract]   [Full Text] [Related]  

  • 15. Sintilimab plus IBI305 for hepatocellular carcinoma.
    Bomze D; Meirson T; Azoulay D
    Lancet Oncol; 2021 Sep; 22(9):e386. PubMed ID: 34478670
    [No Abstract]   [Full Text] [Related]  

  • 16. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Hou Y; Wu B
    Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
    [No Abstract]   [Full Text] [Related]  

  • 17. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
    Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
    J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
    Cheng AL
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
    [No Abstract]   [Full Text] [Related]  

  • 19. Sintilimab plus IBI305 for hepatocellular carcinoma - Author's reply.
    Fan J
    Lancet Oncol; 2021 Sep; 22(9):e388. PubMed ID: 34478672
    [No Abstract]   [Full Text] [Related]  

  • 20. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
    Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
    Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.